CareerCross uses cookies to enhance your experience on our websites. If you continue to view our sites without changing your browser settings, then it is assumed that we have your consent to collect and utilise your cookies. If you do not want to give us your consent, then please change the cookie settings on your browser. Please refer to our privacy policy for more information.
CareerCross uses cookies to enhance your experience on our websites. If you continue to view our sites without changing your browser settings, then it is assumed that we have your consent to collect and utilise your cookies. If you do not want to give us your consent, then please change the cookie settings on your browser. Please refer to our privacy policy for more information.
We work to contribute to a better future by delivering regenerative medicine to patients.
We know that the treatment of intractable diseases also results in our happiness. In research and development to deliver promising cellular medicinal products to patients as early as possible, we see it as important to understand the law according to which cells efficiently function.
We provide seven exceptional features through Animal Origin-Free (AOF) medium technology.
Basic technology
Designed MSC" optimized for each disease
The serum-free nature enables modification of a variety of cellular characteristics.
In addition, a library of chemicals to produce cells with modified characteristics enables selection of the best cells for target diseases.
Culture technology with specifications necessary for clinical practice
A culture system that is free from human / animal-derived components throughout all processes.
This system is characterized by media showing excellent cell growth.
Exosome & culture conditioned medium
Our culture conditioned medium, which are characterized by the safety of AOF and high content of exosomes, have proven to be effective in multiple disease animal models. Their use as samples for research will provide strong support for development.
Intellectual property strategy
Our culture conditioned medium, which are characterized by the safety of AOF and high content of exosomes, have proven to be effective in multiple disease animal models. Their use as samples for research will provide strong support for development.
Business
Clinical development
「Mesenchymal Stem Cells (MSCs)」
Mesenchymal stem cells have potential for effective treatments in various disease areas, such as cardiovascular diseases, central nervous system diseases, autoimmune disorders, gastrointestinal diseases, and respiratory diseases, and are increasingly developed and put to practical use around the world. We will work on the expansion of our development pipeline, beginning at systemic sclerosis and infertility, for which no effective treatment is available.
License business
For mesenchymal stem cells under development, BioMimetics Sympathies licenses the rights for the development, manufacture, and sales in Japan and overseas or work on joint development. We address consultations about licenses by indication, area, and right from development seeds before proceeding to clinical studies to the development stage after proceeding to clinical studies.
In addition, we accept consultations about the license or transfer of know-how and patents owned by us.
Business development consulting
BioMimetics Sympathies provides business development consulting in the development of new businesses / development of medical devices.
We provide total support for the development and promotion of new businesses by creating a business concept, developing a business / action plan, and establishing an alliance system as the foundation for business operation and a cooperation system with medical institutions / doctors.
Sales of cosmetic ingredients
Regenerative medicine support business
We provide support related to the design of cell-processing centers (CPCs), facility management, training, and submission of a plan to provide regenerative medicine for medical institutions providing regenerative medicine or companies entrusted as specified cell-processing business operators with cell cultures under the Act on the Safety of Regenerative Medicine.